2017_SBRT_Course Book

Local tumor control after spine SBRT

Study

# Pat / Tx

FU (months)

SBRT Dose

Local control

Ryu 2004 Henry Ford Hospital

49 / 61

6 – 24

1 x 10-16Gy

84% @ 1a

Gerszten 2007 Pittsburgh Chang 2007 M. D. Anderson Yamada 2008 MSKCC

49 / 65

Median 21

1 x 12.5 - 25Gy

90%

38 / -

Median 21

6 x 5Gy, 3 x 9Gy

84% @ 1a

93 / 103

Median 15

1 x 18 – 24Gy

90% @ 2a

Guckenberger 2009 Würzburg

14 / 16

Median 17

20 x 3Gy

89% @ 2a

Sahgal 2009 PMH / Stanford

14 / 23

Median 9

3 x 8Gy

78%

Balagamwana 2012 Cleveland Clinic

57 / 85

Median 5.4

1 x 15Gy

71% @ 1a

Garg 2012 M. D. Anderson

61 / 63

Median 20

1 x 16-24Gy

88 @ 1.5a

MF: 96% @ 2a SF: 70% @ 2a

Heron 2012 Pittsburgh and Georgetown Schipani 2012 Henry Ford Hospital

228 / 348

Median 12

1 – 5 Fx

124 / 165

Median 7

1 x 18Gy

ESTRO SBRT 2017 - Matthias Guckenberger

07.09.17

33

/

DOSIS: a multi-center phase II trial

Prospective phase II trial • 54 patients with 60 vertebral metastases • No exclusion of patients with epidural disease • Fractionated SBRT • SBRT using SIB concept: • 5 x 4 / 7Gy • 10 x 3 / 4.85Gy • Selection of patients with long OS expectancy

ESTRO SBRT 2017 - Matthias Guckenberger

07.09.17

34

/